Medical News

RSS

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

Domiciliary parenteral nutrition helps children with serious intestinal problems live more normally

Children with serious intestinal problems have to be fed intravenously. There moreover, exist systems that enable intravenous feeding to be carried out at home. Mr I-aki Irastorza, paediatrician at the Cruces hospital in Bilbao, spent some 15 years analysing how serious intestinal problems in children were treated at the Great Ormond Street Children's Hospital in London. With the gathered data he has presented a highly novel PhD thesis at the University of the Basque Country.

9 Mar 2010

TechniScan commences study with WBU system for automated breast ultrasound imaging

TechniScan, Inc., a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it has commenced phase two of its grant study at the University of California, San Diego (UCSD) Moores Cancer Center.

9 Mar 2010

Collagenna Skin care Products enters into exclusive distribution agreement with Alphaderm Body and Wellness

Hard to Treat Diseases announces that Collagenna Skin care Products has entered into an exclusive distribution agreement with Alphaderm Body and Wellness for Switzerland.

9 Mar 2010

Avizent expands in-house Loss Control program to help employers meet stricter OSHA guidelines

Employers nationwide are recognizing that the federal government intends to expand and strengthen Occupational Safety and Health Administration (OSHA) authority, and ensure strict adherence to industry-specific guidelines. National claims and risk management service provider Avizent is preparing for these changes by expanding its in-house Loss Control program to serve clients nationwide.

9 Mar 2010

Envy Medical launches new Lumixyl Brightening System for treating hyperpigmentation

Envy Medical, Inc., introduces the new Lumixyl™ Brightening System, a revolutionary multi-faceted approach to effectively treat hyperpigmentation without irritation or other side effects associated with prescription Hydroquinone or retinoids. This professional skincare system introduction builds on the success of the Lumixyl Topical Brightening Creme introduced in 2009.

9 Mar 2010

Self-rated quality of life predicts long-term survival for esophago-gastric cancer

Changes in patients' self-rated quality of life after treatment for esophago-gastric cancer can predict the chances for long-term survival. This is the result researchers at the Swedish medical university Karolinska Institutet made, in a new study published in the Journal of Clinical Oncology.

9 Mar 2010

EUCODIS Bioscience introduces phospholipases

EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has launched a panel of phospholipases, adding a new enzyme family to its product portfolio.

9 Mar 2010

Study validates Chronix Biomedical’s serum DNA blood tests for early, accurate detection of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests for the early and accurate detection of breast cancer. The Chronix tests detect the circulating DNA that is released into the blood stream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseases—changes that can be used to identify disease processes at an early stage and to track responses to treatment.

9 Mar 2010

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration meets today to review and discuss the company's New Drug Application for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis.

9 Mar 2010

AHF’s Magic Johnson ‘Testing America’ Tour arrives in Charlotte, North Carolina

AHF’s Magic Johnson ‘Testing America’ Tour, a six month, 48 state national cross country HIV testing tour, arrives in Charlotte, North Carolina and will offer free HIV testing, along with local partner the Regional HIV/AIDS Consortium, today Tuesday, March 9th at Greater Mt. Moriah Baptist Church, 727 West Trade Street, from 12:00 noon until 6:00 pm.

9 Mar 2010

Trinity Health goes live with first stage of Novo Grid deployment

Medicity, Inc. announced today that top-ranked health system Trinity Health, comprised of 44 hospitals and numerous healthcare facilities in eight states, went live with the first stage of its Novo Grid deployment – establishing electronic health information exchange (HIE) with 297 affiliated physician practices and 991 physicians in three months.

9 Mar 2010

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.

9 Mar 2010

First Edition: March 9, 2010

Today's headlines reflect the latest news on President Obama's effort to build support -- both among the public and lawmakers-- for his health plan. Meanwhile, the GOP pledges to make the reform face off a key issue in the midterm elections.

9 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

"Cyberbullying" leads to depression in LGBT youth

Schools are typically on guard against students who bully by inflicting repeated violence on other students. But technology has given rise to a relatively new form of bullying which inflicts emotional harm in a stealth manner, working through Web sites, chat rooms, e-mail, cell phones and instant messaging.

9 Mar 2010

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

Quantros announces support for National Patient Safety Week with video about Clinical Cafe

Quantros, a leading healthcare software and services provider of data management, decision support analytics, and clinical business intelligence solutions, today announced its support for National Patient Safety Week with a video about Quantros' Clinical Cafe, a new online networking community for healthcare professionals working in patient safety, quality of care and regulatory compliance.

9 Mar 2010

Novel protein haditoxin in King Cobra's venom discovered

The King Cobra continues to weave its charm with researchers identifying a protein in its venom with the potential for new drug discovery and to advance understanding of disease mechanisms.

9 Mar 2010

New article sheds light on the costs and benefits of screening for SMA

Spinal Muscular Atrophy is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. Although the American College of Medical Genetics recommends carrier testing for all couples, the American College of Obstetricians and Gynecologists has issued a recommendation to the contrary, citing lack of information about the costs and benefits of screening for SMA.

9 Mar 2010

Medical News

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Domiciliary parenteral nutrition helps children with serious intestinal problems live more normally

TechniScan commences study with WBU system for automated breast ultrasound imaging

Collagenna Skin care Products enters into exclusive distribution agreement with Alphaderm Body and Wellness

Avizent expands in-house Loss Control program to help employers meet stricter OSHA guidelines

Envy Medical launches new Lumixyl Brightening System for treating hyperpigmentation

Self-rated quality of life predicts long-term survival for esophago-gastric cancer

EUCODIS Bioscience introduces phospholipases

Study validates Chronix Biomedical’s serum DNA blood tests for early, accurate detection of breast cancer

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

AHF’s Magic Johnson ‘Testing America’ Tour arrives in Charlotte, North Carolina

Trinity Health goes live with first stage of Novo Grid deployment

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

First Edition: March 9, 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

"Cyberbullying" leads to depression in LGBT youth

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Quantros announces support for National Patient Safety Week with video about Clinical Cafe

Novel protein haditoxin in King Cobra's venom discovered

New article sheds light on the costs and benefits of screening for SMA

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News